SFDA Accelerated Approval Oncology: Expanding Access with Anktiva in Saudi Arabia

Key Takeaways

• World-first approval: SFDA became the first regulatory authority globally to approve Anktiva for metastatic NSCLC in combination with checkpoint inhibitors for patients who progressed after standard therapies [SFDA, January 2026].
• Dual indication authorization: The SFDA approved Anktiva for both metastatic NSCLC and BCG-unresponsive NMIBC with carcinoma in situ, expanding treatment options for Saudi patients with limited therapeutic alternatives.
• IL-15 mechanism: Anktiva is a first-in-class IL-15 receptor agonist that activates natural killer cells, CD8+ killer T cells, CD4+ helper T cells, and memory T cells without expanding regulatory T cells [FDA, April 2024].
• Clinical outcomes: NMIBC trials demonstrated a 62% complete response rate; NSCLC approval was based on QUILT-3.055 basket trial data showing potential survival improvement in checkpoint inhibitor-relapsed patients.
• MENA expansion: ImmunityBio established a Saudi subsidiary and partnered with Biopharma Cigalah for regional commercialization.

What is Anktiva and How Does It Work?

Anktiva (nogapendekin alfa inbakicept-pmln) represents a novel class of cancer immunotherapy. It functions as an interleukin-15 (IL-15) receptor agonist, binding to the IL-15 receptor beta-gamma complex on immune cells. This binding triggers proliferation and activation of natural killer (NK) cells, CD4+ T helper cells, and CD8+ killer T cells. Crucially, Anktiva also stimulates memory T cells while limiting expansion of immuno-suppressive regulatory T cells (Tregs).

The drug's mechanism mimics dendritic cell biology, activating what ImmunityBio terms the "triangle offense" of tumor cell killing. This involves NK cells, CD8+ killer T cells, and memory T cells working together to create durable anti-tumor responses. The IL-15 pathway differs from checkpoint inhibitors, which work by blocking inhibitory signals rather than directly activating immune cells.

SFDA Approvals: Two Cancer Indications

BCG-Unresponsive Bladder Cancer

The SFDA approved Anktiva for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. Patients receive Anktiva via intravesical instillation directly into the bladder in combination with Bacillus Calmette-Guérin (BCG). This approval followed the drug's earlier FDA authorization in April 2024 [FDA Approval Package, April 2024].

The QUILT-3.032 trial (NCT03022825) provided the primary clinical evidence. In this Phase II/III single-arm study of 77 evaluable patients, Anktiva plus BCG achieved a 62% complete response rate. Durable responses exceeded 47 months with ongoing follow-up. Grade 3/4 adverse events ranged from 0% to 3%, demonstrating tolerable safety.

Metastatic Non-Small Cell Lung Cancer

The SFDA's approval for metastatic NSCLC represents a world-first regulatory authorization. Anktiva is approved in combination with immune checkpoint inhibitors for adult patients whose disease progressed after standard-of-care therapy, including prior checkpoint inhibitor treatment.

Data from the QUILT-3.055 basket trial supported this conditional approval. The trial enrolled patients who had not responded to one or more prior therapies, including checkpoint inhibitors. Early findings suggested potential survival improvement in this heavily pre-treated population. The SFDA granted conditional approval requiring confirmatory trials to demonstrate long-term clinical benefit.

For NSCLC, Anktiva is administered via subcutaneous injection. This marks the first approval worldwide for subcutaneous Anktiva plus checkpoint inhibitor combination.

Clinical Safety Profile

The SFDA disclosed adverse event data from both cancer trials. In bladder cancer studies, the most common side effects included:

Adverse Event	Description
Renal effects	Elevated creatinine levels
Urinary symptoms	Dysuria (painful urination), hematuria (blood in urine), urinary urgency and frequency
Infections	Urinary tract infections
Electrolyte changes	Increased potassium (hyperkalemia)
Systemic effects	Musculoskeletal pain, chills, fever

In lung cancer trials, common adverse events included injection-site reactions (redness, pain, itching), chills, fatigue, fever, nausea, influenza-like symptoms, and decreased appetite.

How Does SFDA's Accelerated Pathway Work?

The SFDA operates a breakthrough medicine program that facilitates accelerated development and review of drugs addressing unmet medical needs in serious or life-threatening conditions. This program mirrors similar pathways at the U.S. FDA and European Medicines Agency but operates independently with Saudi-specific criteria.

For Anktiva's NSCLC indication, the SFDA granted conditional approval based on early clinical signals of benefit in a population with no approved alternatives after checkpoint inhibitor failure. This conditional status requires confirmatory evidence to maintain approval. The regulatory decision reflects the SFDA's risk-benefit assessment that potential benefits outweighed uncertainties given the fatal nature of metastatic NSCLC and lack of treatment options for this patient subset.

Market Impact and MENA Expansion

ImmunityBio has committed significant resources to the Saudi market. The company established a wholly owned subsidiary in the Kingdom and partnered with Biopharma Cigalah, a leading regional pharmaceutical distributor, to commercialize Anktiva across the Middle East and North Africa.

The approval aligns with Saudi Vision 2030's Health Sector Transformation Program objectives. By approving innovative therapies like Anktiva, the SFDA supports national goals to elevate healthcare quality and strengthen Saudi Arabia's regional leadership in pharmaceutical regulation.

Bladder and lung cancer incidence in the MENA region is rising, creating significant unmet need. Anktiva provides a potential bladder-sparing option for NMIBC patients who would otherwise face cystectomy. For NSCLC patients, it offers a new therapeutic avenue after checkpoint inhibitor failure.

What Regulatory Developments Are Next?

Several regulatory developments may affect Anktiva's trajectory in Saudi Arabia:

• Confirmatory trials: The SFDA requires confirmatory studies to maintain conditional NSCLC approval. ImmunityBio has initiated discussions to expand Anktiva plus checkpoint inhibitors into additional tumor types.
• Recombinant BCG: The SFDA encouraged ImmunityBio to submit a regulatory package for recombinant BCG to address global BCG shortages affecting bladder cancer patients.
• Regional expansion: ImmunityBio is pursuing approvals across additional MENA countries, using the Saudi approval as a regulatory precedent.

The QUILT-2.005 randomized trial comparing BCG alone versus BCG plus Anktiva in BCG-naïve NMIBC patients is ahead of schedule, with full enrollment anticipated by Q2 2026. This trial could support expanded labeling.

Frequently Asked Questions

Primary Sources

1. Saudi Food and Drug Authority. SFDA Approves Registration of "Anktiva" for the Treatment of Bladder and Lung Cancer. January 16, 2026.
2. ImmunityBio, Inc. Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA for Non-Muscle Invasive Bladder Cancer. January 14, 2026.
3. U.S. Food and Drug Administration. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. April 22, 2024.
4. U.S. Food and Drug Administration. NDA Approval Package for ANKTIVA (nogapendekin alfa inbakicept-pmln). Application Number 761336. April 22, 2024.
5. ClinicalTrials.gov. QUILT-3.032: A Multicenter Clinical Trial of Intravesical BCG in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer. NCT03022825.
6. ImmunityBio, Inc. Investor Relations. ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority. February 17, 2026.